Should Eliquis (apixaban) be held before a paracentesis?

Should Eliquis Be Held Before Paracentesis?

Yes, Eliquis (apixaban) should be held for at least 48 hours before paracentesis, as this procedure carries significant bleeding risk, particularly in patients with liver disease and coagulopathy.

Risk Classification and Management Strategy

Paracentesis presents a unique challenge because while traditionally considered "low-risk," recent evidence demonstrates substantially elevated bleeding rates in patients on apixaban, particularly those with cirrhosis. The FDA label specifies that ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding 1.

Evidence of Elevated Bleeding Risk

The most concerning data comes from a 2025 retrospective study showing 5.5% overall hemorrhage rate and 1.1% fatal hemorrhage rate in patients on apixaban undergoing paracentesis 2. This is dramatically higher than historical estimates for paracentesis without anticoagulation. Critical risk factors identified include:

• Apixaban taken within 6 hours of procedure: 16% bleeding rate
• High-dose apixaban (10 mg twice daily): 38% bleeding rate
• Concurrent antiplatelet/anticoagulant therapy: 19% bleeding rate
• Patients with cirrhosis and renal impairment are at particularly high risk 3

Recommended Holding Protocol

Based on the 2022 ACCP guidelines and FDA labeling:

For standard patients (CrCl >50 mL/min):

• Hold apixaban for 2 days (48 hours) before the procedure 4, 1
• Last dose should be taken 2 days prior to paracentesis

For patients with impaired renal function (CrCl 30-50 mL/min):

• Consider extending the interruption window given reduced drug clearance 4
• The French GIHP guidelines recommend holding xabans for 3 days when CrCl >30 mL/min 5

Bridging is NOT recommended - The guidelines explicitly state that bridging anticoagulation during the 24-48 hours after stopping apixaban is not generally required 1, and bridging has been associated with increased bleeding without thromboembolic benefit 5.

Resumption Strategy

Resume apixaban at least 6 hours after the procedure if there is no ongoing bleeding 5, 1. The FDA label states to restart "as soon as adequate hemostasis has been established" 1.

For twice-daily dosing:

• Resume the evening of the procedure day if hemostasis is adequate
• If bleeding risk persists, delay resumption and consider pharmacologic VTE prophylaxis 5

Critical Caveats

Do NOT rely on the older literature suggesting paracentesis is universally "low-risk" - A 2025 study showed only 1.4% bleeding in prophylactic anticoagulation but this included patients where anticoagulation was appropriately held 6. The key distinction is that patients with cirrhosis on apixaban represent a uniquely high-risk population due to:

• Impaired hepatic drug metabolism leading to elevated apixaban concentrations 3
• Baseline coagulopathy from liver disease
• Thrombocytopenia
• Portal hypertension with varices

Avoid these common errors:

• Treating paracentesis as universally "low-risk" requiring only 24-hour hold
• Failing to account for renal function when timing cessation
• Adding bridging anticoagulation (increases bleeding risk)
• Resuming too early before adequate hemostasis

The evidence strongly supports a conservative 48-hour hold for apixaban before paracentesis, with particular caution in cirrhotic patients, those on high doses, or with concurrent antiplatelet therapy 2, 3.